Abstract: A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
Type:
Application
Filed:
February 27, 2014
Publication date:
June 26, 2014
Applicant:
ORION CORPORATION
Inventors:
David DIN BELLE, Patrik HOLM, Arto KARLJALAINEN, Arto TOLVANEN, Gerd WOHLFAHRT, Petteri RUMMAKKO
Abstract: A compound of formula (I) wherein R1 to R15, P1, P2, A, B and Q are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds of formula (I) possess utility as matriptase inhibitors and are useful in the treatment of matriptase dependent conditions, particularly cancer.
Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
Type:
Grant
Filed:
June 14, 2013
Date of Patent:
April 15, 2014
Assignee:
Orion Corporation
Inventors:
David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
Abstract: The present invention relates to a method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. In addition, the present invention relates to a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof.
Type:
Application
Filed:
June 24, 2013
Publication date:
April 10, 2014
Applicants:
Recro Pharma, Inc., Orion Corporation
Inventors:
Riitta Heino, Tiina Leino, Tarja Lehtimaki
Abstract: Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14?, R15, R15?, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.
Type:
Application
Filed:
April 20, 2012
Publication date:
April 3, 2014
Applicant:
ORION CORPORATION
Inventors:
Olli Törmakängas, Gerd Wohlfahrt, Harri Salo, Rathna Durga Ramasurbamanian, Pranab Kumar Patra, Arputharaj Ebenezer Martin, Terhi Heikkinen, Anniina Vesalainen, Anu Moilanen, Arja Karjalainen
Abstract: A hydrodynamic bearing includes a housing defining a central axis, a pad slidable relative to the housing in a direction substantially parallel to the central axis, a cylinder defined in one of the housing and the pad, a lubricant port in fluid communication with the cylinder, and a piston at least partially positioned in the cylinder. The piston is movable within the cylinder between a retracted position and an extended position in response to a flow of lubricant through the lubricant port to vary an axial spacing between the pad and the housing.
Abstract: An inhaler device includes an air conduit including a mouthpiece and a dosing means adapted to provide a dose of powder to the air conduit for entrainment in the stream of air. In the area downstream from the dosing means the wall of the air conduit is provided with a secondary air inlet extending to the direction of the mouthpiece such that the entry of secondary air occurs over an extended length of the air conduit downstream from the dosing means.
Type:
Grant
Filed:
June 20, 2002
Date of Patent:
October 8, 2013
Assignee:
Orion Corporation
Inventors:
Kari Seppälä, Terhi Mattila, Kalle Purma, Markku Härkönen
Abstract: A compound of formula (I), an isomer, metabolite, or a pharmaceutically acceptable salt or ester thereof is disclosed. Compounds of the invention possess utility as a tissue-selective androgen receptor modulators (SARM) and are useful in hormonal therapy, e.g. in the treatment or prevention of hypogonadism, muscle wasting, osteoporosis, benign prostate hyperplasia, obesity associated with a metabolic syndrome, male and female sexual dysfunction and reduced libido, and androgen decline in aging male or female.
Type:
Grant
Filed:
March 2, 2007
Date of Patent:
August 6, 2013
Assignee:
Orion Corporation
Inventors:
Jari Ratilainen, Olli Törmäkangas, Arja Karjalainen, Paavo Huhtala
Abstract: Compounds of formula I wherein X, Z, R1-R4, and m are as defined in the claims, exhibit alpha2C antagonistic activity, and are thus useful as alpha2C antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed.
Type:
Grant
Filed:
July 18, 2008
Date of Patent:
July 23, 2013
Assignee:
Orion Corporation
Inventors:
David Din Belle, Patrik Holm, Arto Karljalainen, Arto Tolvanen, Gerd Wohlfahrt, Petteri Rummakko
Abstract: The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.
Type:
Application
Filed:
March 3, 2011
Publication date:
May 30, 2013
Applicant:
ORION CORPORATION
Inventors:
Juha Rouru, Mikko Kuoppamäki, Juha Ellmen, Pekka Männistö